Formulation, Optimization,
Adamantane
/ administration & dosage
Administration, Oral
Adult
Biological Availability
Delayed-Action Preparations
/ pharmacokinetics
Dipeptides
/ administration & dosage
Drug Compounding
/ methods
Drug Delivery Systems
/ methods
Drug Liberation
/ physiology
Fatty Acids
/ pharmacokinetics
Half-Life
Healthy Volunteers
Humans
Liposomes
/ pharmacokinetics
Male
Models, Statistical
Solubility
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
04
2021
revised:
20
08
2021
accepted:
15
09
2021
entrez:
1
11
2021
pubmed:
2
11
2021
medline:
27
1
2022
Statut:
epublish
Résumé
The development and optimization of controlled release lipospheres (LS) from safe biocompatible behenic acid (BA) was performed for not only enhancing patient's compliance against highly prevailed chronic diabetes but also to vanquish the insufficiencies of traditional methods of drug delivery. The Box-Bhenken design (BBD) was utilized to statistically investigate the impact of formulation variables on percentage yield (
Identifiants
pubmed: 34722762
doi: 10.1155/2021/3849093
pmc: PMC8550843
doi:
Substances chimiques
Delayed-Action Preparations
0
Dipeptides
0
Fatty Acids
0
Liposomes
0
saxagliptin
9GB927LAJW
behenic acid
H390488X0A
Adamantane
PJY633525U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3849093Informations de copyright
Copyright © 2021 Akhtar Rasul et al.
Déclaration de conflit d'intérêts
The authors declared that there is no conflict of interest associated with this work.
Références
Clin Pharmacokinet. 2017 Jan;56(1):11-24
pubmed: 27282159
Comput Methods Programs Biomed. 2010 Sep;99(3):306-14
pubmed: 20176408
Indian J Pharm Sci. 2009 Mar;71(2):148-51
pubmed: 20336215
Acta Pol Pharm. 2017 Jan;74(1):211-226
pubmed: 29474777
Drug Dev Ind Pharm. 2012 Sep;38(9):1068-76
pubmed: 22149472
Expert Opin Drug Metab Toxicol. 2017 May;13(5):583-592
pubmed: 28374622
PLoS One. 2018 Aug 30;13(8):e0203405
pubmed: 30161251
Drug Deliv. 2013 Apr-May;20(3-4):102-11
pubmed: 23650987
Iran J Basic Med Sci. 2012 Jan;15(1):608-24
pubmed: 23492721
Expert Opin Drug Deliv. 2005 Jan;2(1):75-87
pubmed: 16296736
Acta Pharm. 2007 Sep;57(3):269-85
pubmed: 17878108
Curr Drug Deliv. 2014;11(1):72-86
pubmed: 24783236
Int J Pharm. 2004 Apr 15;274(1-2):1-33
pubmed: 15072779
Drug Deliv. 2016 Sep;23(7):2371-2390
pubmed: 25544604
Curr Drug Deliv. 2009 Oct;6(5):477-85
pubmed: 19863493
J Microencapsul. 2001 May-Jun;18(3):277-84
pubmed: 11308219
AAPS PharmSciTech. 2008;9(1):154-62
pubmed: 18446476
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
Br J Clin Pharmacol. 1990 Jan;29(1):39-45
pubmed: 2404502
J Pharm Pharmacol. 2009 Mar;61(3):311-21
pubmed: 19222903
Drug Dev Ind Pharm. 2009 Oct;35(10):1155-66
pubmed: 19555239
Arch Pharm Res. 2009 Jul;32(7):1019-28
pubmed: 19641883
AAPS PharmSciTech. 2006 May 26;7(2):E47
pubmed: 16796364
Curr Drug Deliv. 2014;11(4):444-57
pubmed: 24438443